ClinicalTrials.gg
CompletedNCT00611559Updated Jun 6, 2018Results posted

Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children

A Phase 4 interventional study of Infanrix™ penta and Infanrix™ hexa in Poliomyelitis, Acellular Pertussis and Tetanus, sponsored by GlaxoSmithKline. Completed at 3 sites in Russian Federation. Open to participants aged 18 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
18 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Poliomyelitis.

Enrollment
11th of 14
283 · median 467
Started
2008
with 2 others
Phase 4
5 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
13 of 14
GlaxoSmithKline

Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, this one is the 11th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 4, and was the 4th registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

None of the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis is open now. The open studies under Poliomyelitis, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis as a file.
02

Study summary

The new formulation administered as a 4th consecutive dose will be compared to the current formulation of the vaccine in this partially double blind study.

The study will be double-blind with respect to the two DTPa-HBV-IPV/Hib groups. The study will be open with respect to the DTPa-HBV-IPV group.

03

Conditions studied

  • Poliomyelitis
  • Acellular Pertussis
  • Tetanus
  • Diphtheria
  • Hepatitis B

Keywords

  • Infanrix hexa
  • combined vaccine
04

Who can participate

Ages eligible
18 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • Subjects must have completed full three-dose primary vaccination course with DTPa--IPV/Hib or DTPa-HBV-IPV in the primary study DTPa-HBV-IPV-109 (study NCT00320463).
  • A male or female between, and including 18 and 23 months of age at the time of the booster vaccination.
  • Written obtained from the parent or guardian of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccines within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the booster dose.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the booster dose.
  • Participation in another clinical study, between the primary study NCT00320463 and the present booster study, or at any time during the study, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous booster vaccination against diphtheria, tetanus, pertussis, poliomyelitis and since the conclusion visit of study NCT00320463.
  • Previous booster vaccination against Haemophilus influenzae diseases in the DTPa-HBV-IPV/Hib groups, since the conclusion visit of study NCT00320463.
  • History of exposure to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and/or Haemophilus influenzae disease since the conclusion visit of study NCT00320463.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
  • Any of the following adverse events having occurred after previous administration of DTP vaccine:
  • reaction due to the vaccine.
  • Encephalopathy defined as an acute, severe central nervous system disorder of unknown etiology occurring within 7 days following previous vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours.
  • Any of the following adverse events having occurred after previous administration of DTP vaccine:
  • Temperature of >= 40.0 °C (axillary temperature), within 48 hours of vaccination.
  • Collapse or shock-like state within 48 hours of vaccination.
  • Persistent, inconsolable crying lasting >= 3 hours, occurring within 48 hours of vaccination.
  • Convulsions with or without fever, occurring within 3 days of vaccination
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Infanrix hexa Preservative-Free Formulation Group

    Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa

    Biological: Infanrix™ hexa

  • Active comparator
    Infanrix hexa Preservative-Containing Formulation Group

    Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa

    Biological: Infanrix™ hexa

  • Active comparator
    Infanrix penta Preservative-Free Formulation Group

    Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.

    Biological: Infanrix™ penta

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose

    Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)

    Time frame: One month after the booster dose

  2. Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose

    Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)

    Time frame: One month after the booster dose

  3. Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose

    Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)

    Time frame: One month after the booster dose

  4. Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose

    Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)

    Time frame: One month after the booster dose

  5. Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose

    Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)

    Time frame: One month after the booster dose

Secondary outcomes

  1. Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose

    Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL Number of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes

    Time frame: Before (Pre) and one month after (Post) the booster dose

  2. Anti-HB Antibodies Concentration

    Concentration of anti-HB antibodies given as GMC in mIU/mL

    Time frame: Before (Pre) and one month after (Post) the booster dose

  3. Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose

    Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL Number of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes

    Time frame: Before (Pre) and one month after (Post) the booster dose

  4. Anti-PRP Antibodies Concentration

    Concentration of anti-PRP antibodies given as GMC in µg/mL

    Time frame: Before (Pre) and one month after (Post) the booster dose

  5. Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose

    Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL

    Time frame: Before the booster dose administration (at baseline)

  6. Anti-diphtheria and Anti-tetanus Antibodies Concentration

    Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL

    Time frame: Before (Pre) and one month after (Post) the booster dose

  7. Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose

    Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL

    Time frame: Before (Pre) and one month after (Post) the booster dose

  8. Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose

    Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL

    Time frame: Before the booster dose administration (at baseline)

  9. Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose

    Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50

    Time frame: Before the booster dose

  10. Anti-poliovirus Antibodies Titer

    Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)

    Time frame: Before (Pre) and one month after (Post) the booster dose

  11. Number of Subjects Reporting Solicited Symptoms

    Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite

    Time frame: Within the 4-day (Day 0-3) post-vaccination period

  12. Number of Subjects Reporting Unsolicited Adverse Events (AE)

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Within the 31-day (Day 0-30) post-vaccination period

  13. Number of Subjects Reporting Serious Adverse Events (SAE)

    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above

    Time frame: Up to one month after the booster dose administration

07

Results

Posted Aug 10, 2009

Participant flow

Participant flow — Overall Study
MilestoneInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Started11111557
Completed11011456
Not completed111
Withdrew: Lost to follow-up010
Withdrew: Protocol violation101

Outcome measures

PrimaryNumber of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose

Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)

Time frame:
One month after the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose889248
PrimaryNumber of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose

Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)

Time frame:
One month after the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose747827
PrimaryNumber of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose

Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)

Time frame:
One month after the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-diphtheria767640
Anti-tetanus767842
PrimaryNumber of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose

Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)

Time frame:
One month after the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-poliovirus type 1555131
Anti-poliovirus type 2555130
Anti-poliovirus type 3555229
PrimaryAnti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose

Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)

Time frame:
One month after the booster dose
Reported as:
Geometric mean · EL.U/mL
Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose
EL.U/mLInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-PT65.5 (49.8 to 86.3)84.2 (61.5 to 115.4)43.9 (22.4 to 85.8)
Anti-FHA476.6 (369.7 to 614.4)428.3 (311.2 to 589.5)221.1 (120.3 to 406.6)
Anti-PRN418.1 (303.2 to 576.6)384.1 (271.3 to 544.0)251.6 (143.9 to 439.7)
SecondaryNumber of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose

Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL Number of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes

Time frame:
Before (Pre) and one month after (Post) the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
≥ 10 mIU/mL Pre878644
≥ 100 mIU/mL Pre575735
≥ 100 mIU/mL Post858739
SecondaryAnti-HB Antibodies Concentration

Concentration of anti-HB antibodies given as GMC in mIU/mL

Time frame:
Before (Pre) and one month after (Post) the booster dose
Reported as:
Geometric mean · mIU/mL
Anti-HB Antibodies Concentration
mIU/mLInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Pre163.5 (114.3 to 233.7)161.2 (111.5 to 232.9)196.9 (124.2 to 312.2)
Post4668.0 (2861.4 to 7615.3)4962.3 (3289.7 to 7485.4)3867.8 (1751.4 to 8541.5)
SecondaryNumber of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose

Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL Number of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes

Time frame:
Before (Pre) and one month after (Post) the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
≥ 0.15 µg/mL Pre555523
≥ 1.0 µg/mL Pre12147
≥ 1.0 µg/mL Post69749
SecondaryAnti-PRP Antibodies Concentration

Concentration of anti-PRP antibodies given as GMC in µg/mL

Time frame:
Before (Pre) and one month after (Post) the booster dose
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibodies Concentration
µg/mLInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Pre0.3 (0.2 to 0.4)0.4 (0.3 to 0.5)0.2 (0.1 to 0.4)
Post25.3 (16.0 to 40.0)34.7 (22.9 to 52.7)0.4 (0.2 to 0.7)
SecondaryNumber of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose

Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL

Time frame:
Before the booster dose administration (at baseline)
Reported as:
Number · subjects
Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-diphtheria454723
Anti-tetanus696239
SecondaryAnti-diphtheria and Anti-tetanus Antibodies Concentration

Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL

Time frame:
Before (Pre) and one month after (Post) the booster dose
Reported as:
Geometric mean · IU/mL
Anti-diphtheria and Anti-tetanus Antibodies Concentration
IU/mLInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-diphtheria Pre0.2 (0.1 to 0.2)0.2 (0.1 to 0.3)0.1 (0.1 to 0.2)
Anti-diphtheria Post2.7 (1.9 to 3.7)3.4 (2.5 to 4.5)2.2 (1.4 to 3.5)
Anti-tetanus Pre0.5 (0.3 to 0.6)0.5 (0.3 to 0.7)0.3 (0.2 to 0.4)
Anti-tetanus Post4.9 (3.6 to 6.7)6.9 (5.3 to 9.0)4.5 (2.8 to 7.4)
SecondaryNumber of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose

Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL

Time frame:
Before (Pre) and one month after (Post) the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-PT Pre454326
Anti-PT Post796625
Anti-FHA Pre776839
Anti-FHA Post866937
Anti-PRN Pre756735
Anti-PRN Post887740
SecondaryAnti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose

Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL

Time frame:
Before the booster dose administration (at baseline)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose
EL.U/mLInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-PT6.6 (5.2 to 8.4)6.2 (5.0 to 7.8)7.1 (5.3 to 9.4)
Anti-FHA24.5 (18.4 to 32.6)22.1 (16.3 to 30.0)23.8 (17.3 to 32.6)
Anti-PRN17.5 (13.4 to 23.0)13.7 (10.3 to 18.1)15.0 (10.3 to 21.9)
SecondaryNumber of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose

Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50

Time frame:
Before the booster dose
Reported as:
Number · subjects
Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-poliovirus type 1464724
Anti-poliovirus type 2464826
Anti-poliovirus type 3474823
SecondaryAnti-poliovirus Antibodies Titer

Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)

Time frame:
Before (Pre) and one month after (Post) the booster dose
Reported as:
Geometric mean · titer
Anti-poliovirus Antibodies Titer
titerInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Anti-poliovirus type 1 Pre106.5 (67.9 to 167.0)120.4 (76.9 to 188.4)85.9 (47.1 to 156.5)
Anti-poliovirus type 1 Post1237.1 (940.7 to 1626.9)1939.8 (1465.1 to 2568.2)979.5 (539.4 to 1778.8)
Anti-poliovirus type 2 Pre144.4 (96.9 to 215.2)102.5 (68.2 to 154.2)95.3 (56.3 to 161.1)
Anti-poliovirus type 2 Post1412.0 (1096.4 to 1818.5)1900.6 (1399.7 to 2580.7)916.3 (498.1 to 1685.5)
Anti-poliovirus type 3 Pre98.7 (68.0 to 143.2)68.9 (47.0 to 101.1)77.5 (41.9 to 143.4)
Anti-poliovirus type 3 Post1485.9 (1041.4 to 2120.3)1828.7 (1303.8 to 2565.1)605.6 (264.0 to 1389.1)
SecondaryNumber of Subjects Reporting Solicited Symptoms

Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite

Time frame:
Within the 4-day (Day 0-3) post-vaccination period
Reported as:
Number · subjects
Number of Subjects Reporting Solicited Symptoms
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Pain353614
Redness545422
Swelling394519
Drowsiness21188
Fever18156
Irritability21214
Loss of appetite22145
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events (AE)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Within the 31-day (Day 0-30) post-vaccination period
Reported as:
Number · subjects
Number of Subjects Reporting Unsolicited Adverse Events (AE)
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Number of Subjects Reporting Unsolicited Adverse Events (AE)892
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAE)

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above

Time frame:
Up to one month after the booster dose administration
Reported as:
Number · subjects
Number of Subjects Reporting Serious Adverse Events (SAE)
subjectsInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
Number of Subjects Reporting Serious Adverse Events (SAE)000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infanrix Hexa Preservative-free Formulation Group0/111 (0%)0/111 (0%)59/111 (53.2%)
Infanrix Hexa Preservative-containing Formulation Group0/115 (0%)0/115 (0%)62/115 (53.9%)
Infanrix Penta Preservative-free Formulation Group0/57 (0%)0/57 (0%)26/57 (45.6%)
Most frequent other events
Most frequent other events
EventInfanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation Group
RednessGeneral disorders54/11154/11522/57
SwellingGeneral disorders39/11145/11519/57
PainGeneral disorders35/11136/11514/57
Loss of appetiteGeneral disorders22/11114/1155/57
DrowsinessGeneral disorders21/11118/1158/57
IrritabilityGeneral disorders21/11121/1154/57
FeverGeneral disorders18/11115/1156/57

Baseline characteristics

Age, Continuous
Age, Continuous(months)Infanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation GroupTotal
Mean21.2 ± 1.6121.3 ± 1.5721.2 ± 1.6221.2 ± 1.59
Sex: Female, Male
Sex: Female, Male(Participants)Infanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation GroupTotal
Female564635137
Male556922146
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Infanrix Hexa Preservative-free Formulation GroupInfanrix Hexa Preservative-containing Formulation GroupInfanrix Penta Preservative-free Formulation GroupTotal
White - Caucasian/European Heritage11111557283
08

Study locations

3 sites
  • GSK Investigational Site
    Murmansk, 183046, Russian Federation
  • GSK Investigational Site
    Perm, 614022, Russian Federation
  • GSK Investigational Site
    Syktyvkar, 167000, Russian Federation
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2008
First posted
Feb 11, 2008
Start
Feb 14, 2008
Primary completionActual
Jun 25, 2008
CompletionActual
Jun 25, 2008
Results first posted
Aug 10, 2009
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00611559
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 11, 2008
Start date
Feb 14, 2008
Primary completion
Jun 25, 2008
Completion
Jun 25, 2008
Results posted
Aug 10, 2009
Last update
Jun 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion